Beyond Air, Inc. (XAIR) Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. IBM
5. META
6. SPY
7. ACN
8. PRIM
9. PFE
10. TSLA

Go back to Beyond Air, Inc. (XAIR) Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn
(NASDAQ: XAIR) Delayed: 0.41 --0 (-0%)
Previous Close $0.41    52 Week High $ 
Open $0.39    52 Week Low $ 
Day High $0.42    P/E N/A 
Day Low $0.39    EPS $ 
Volume 129,161